Postprandial Inflammation and Fatty Acids

Obesity Clinical Trial

— PIFA  

Official title:

Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00977262
• Other study ID #: NL2800108109
• Status: Completed
• Phase: N/A
• First received: September 11, 2009
• Last updated: April 20, 2010
• Start date: October 2009
• Est. completion date: December 2009

Study information

• Verified date: April 2010
• Source: Wageningen University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The main objective is to elucidate the acute effects of an oral intake of either saturated, monounsaturated or polyunsaturated fatty acids on peripheral blood mononuclear cells (PBMC) whole genome expression of obese and type 2 diabetic obese subjects.

Description:

Consumption of high-fat diets can lead to postprandial dyslipidemia, impairment of endothelial function, activation of immune cells and changes in gene expression profiles of immune cells such as peripheral blood mononuclear cells (PBMC). Recently it was shown that postprandial gene expression profiles of PBMC and plasma triglyceride (TG) and free fatty acid (FFA) responses are dependent on the type of dietary fat consumed (i.e. saturated, monounsaturated and polyunsaturated). Since obese and diabetic subjects usually are in a pro-inflammatory state and have dyslipidemia and endothelial dysfunction we are interested in the effect of different fatty acids in a high load on the PBMC gene expression profiles, plasma cytokine profiles and endothelial function of these subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

For all participants:

• male gender

• 50-70 yrs

For diabetic patients only:

• BMI >30 kg/m2

• Well-controlled diabetes: fasting plasma glucose concentration must be <10.0 mmol/l at the time of screening.

• Must be on sulphonylurea- or metformin therapy for at least 6 months with a constant dose for at least two months, or on dietary treatment for at least 6 months2.

For obese controls only:

• BMI > 30 kg/m2

• normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

For lean controls only:

• BMI 18-25 kg/m2

• normoglycemic according to WHO criteria (OGTT, fasting blood glucose< 7 mmol/L, after 2 hr <7.8mmol/L)

Exclusion Criteria:

For all participants:

• Female gender

• Age below 50 or above 70 years

• Hemoglobin levels <8.4 mmol/L

• Allergic to cow milk or dairy products

• Allergic to fish oil

• Vegetarian

• Tobacco smoker

• Current or recent (<4 weeks) use of fish oil supplements or more then four times fish/week; 24.35 g of EPA-DHA of fish per month (800 mg/day) as judged by the questionnaire.

• Received inoculations within 2 months of starting the study or planned to during the study

• Donated or intended to donate blood from 2 months before the study till two months after the study

• Unstable body weight (weight gain or loss > 3 kg in the past three months)

• Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, gastrointestinal disease, renal dysfunction)

• Use of medications know to interfere with glucose homeostasis (i.e. corticosteroids)

• abuse of drugs and/or alcohol

• participation in another biomedical study within 1 month before the first screening visit

For obese, type 2 diabetic subjects only:

• severe diabetes which requires application of insulin

• diabetes-related complications

For obese subjects and lean controls only:

• hyperglycemic according to WHO criteria (OGTT, fasting blood glucose >6.0mM, after 2 hr>11mM)

• systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg

• Urinary glucose concentrations (>0.25 g/l)

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Diabetes Mellitus, Type 2
• Diabetes Type 2
• Obesity

Intervention

Other:
• High saturated fat shake
milkshake containing 95 gram of fat, high percentage of saturated fat
• High monounsaturated fat shake
milkshake containing 95 gram of fat, high percentage of monounsaturated fat
• High polyunsaturated fat shake
milkshake containing 95 gram of fat, high percentage polyunsaturated fat

Locations

Country	Name	City	State
Netherlands	Wageningen University, Division of Human Nutrition	Wageningen	Gelderland
Netherlands	Wageningen University, Division of Human Nutrition	Wageningen

Sponsors (2)

Lead Sponsor	Collaborator
Wageningen University	Dutch Diabetes Research Foundation

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PBMC gene expression profiles		0, 2, 4 hrs	No
Secondary	PBMC inflammatory response capacity		0, 2, 4 hrs	No
Secondary	Endothelial function		0, 2, 4 hrs	No